Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 22Tumor-Agnostic 4Breast 4Thoracic 2Other solid neoplasm 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gastrointestinal 1Classical hematology 1CNS 1

Conditions

Small Cell Lung Carcinoma 1Recurrence 1Neoplasm Metastasis 1Lung Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × XRP6258 × Thoracic × Clear all
NCT02166658 2018-01-23

CaBaMet

AIO-Studien-gGmbH

Phase 2 Terminated
8 enrolled
BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Recurrence

NCT01500720 2015-04-13

Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer

Sanofi

Phase 2 Completed
179 enrolled 16 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡